January 2014 in “Progress of Digestive Endoscopy” Prednisolone improved symptoms in a woman with Cronkhite-Canada syndrome, but regular screenings are needed due to cancer risk.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
34 citations
,
May 1987 in “European Journal of Pediatrics” Buserelin safely and effectively suppresses early puberty, potentially improving final height.
55 citations
,
July 2013 in “Dermatologic therapy” Some dermatological medications can impair male fertility, so consult a doctor before trying to conceive.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
December 2025 in “JEADV Clinical Practice” These new skin treatments are safer and more effective with minimal side effects.
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
January 2022 in “Current Enzyme Inhibition” New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
June 2008 in “Experimental Dermatology” 17-beta estradiol and prednisolone may help regrow hair damaged by chemotherapy.
November 2024 in “PubMed” Terbinafine can cause skin reactions when exposed to sunlight, so sun exposure should be avoided during treatment.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
April 2023 in “Journal of Investigative Dermatology” Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
20 citations
,
July 1990 in “Clinical and experimental dermatology” Taking cyproterone acetate and ethinyl oestradiol for hair loss can lower vitamin B12 levels in women.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
10 citations
,
April 2020 in “Dermatology and therapy” Calcipotriol works almost as well as clobetasol for mild to moderate alopecia areata with fewer side effects.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
8 citations
,
March 2019 in “Drugs - Real World Outcomes” Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
10 citations
,
September 2016 in “Journal of cutaneous medicine and surgery” Patients on dabrafenib and trametinib for melanoma often experience skin side effects.
68 citations
,
May 1991 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Both cyproterone acetate and spironolactone effectively reduce hair growth in women with hirsutism.
11 citations
,
December 2013 in “Clinical and Experimental Dermatology” Sorafenib often causes skin side effects, indicating effective cancer treatment.
65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
17 citations
,
December 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists found new, better-working inhibitors for a hormone-related enzyme.
1 citations
,
January 2009 in “X-ray Structure Analysis Online” A new compound was made that might help treat diseases related to male hormones.
6 citations
,
January 2013 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” A new compound shows promise as a topical treatment for hair loss.
1 citations
,
November 2023 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib helps with early hair regrowth in people with alopecia areata.
24 citations
,
February 2007 in “Hormone and metabolic research” The substance MK386 effectively blocked testosterone conversion and reduced cell growth in certain skin cells, but inhibiting 5α-reductase alone may not greatly improve acne.
3 citations
,
December 2022 in “Russian Journal of General Chemistry” CoCr2O4 catalysts effectively and sustainably produce diaminopyrimidine oxides with high yield.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.